This level is similar to previous reports of other LBD-lacking AR variants (expressed at <5% of the levels of wild-type AR in breast and prostate cancer cell lines and tissues), although they may be expressed more highly in some prostate cancer cell lines and clinical prostate cancer specimens [5,15,21]. This evidence concerns the gene AR and prostate carcinoma.